Home About Us Our Vision Our Team Portfolio Inv. Relations News Contact Us

Click here to view all of Teuza's portfolio companies (print version - pdf format)


Teuza's holdings: 13%

Sealantis develops surgical adhesive products based on its breakthrough ALGA MIMETIC platform technology.

Sealantis translated the unique ability of algae to adhere to surfaces in wet environment into a medical device to be used in a wide range of surgical applications in the >$2.5B Biosurgicals market.

The company was founded at AMIT - Alfred Mann Institute at the Technion by Prof. Havazelet Bianco-Peled, a renown biopolymer researcher.

Sealantis’ main product is a Gastro Intestinal (GI) Sealant. In millions of surgical procedures on the gastro-intestinal (GI) system, surgical incisions are made and then closed with sutures and \ or staples. While sutures and staples are the standard of care for surgical wound closure, they are incapable of water-tight sealing of wounds. Bowel content leakage from GI incisions is one of the complications most dreaded by GI surgeons, due to its potential fatal implications. In addition to the significant morbidity and mortality, GI anastomotic leaks are associated with a 56% increase in the length of stay and with an additional cost of $28,000 per patient on average.

Sealantis developed Seal-G, a Gastro-Intestinal (GI) bioresorbable sealant designed to prevent leakage of bowel content from GI suture- or staple-lines thereby preventing the morbidity and mortality associated with post-surgical leaks.

P.O.B 25266 Haifa 31250 Israel Tel: 972 4 8728788 Fax: 972 4 8729393 E-mail: teuza@teuzafund.com